CLINICAL GUIDANCE FRAMEWORKS
|
|
- Joanna Cummings
- 5 years ago
- Views:
Transcription
1 IMPROVING CARE PROCESSES FOR PATIENTS WITH POSSIBLE SUSPECTED ACUTE CORONARY SYNDROME (ICARE-ACS): A NATIONAL IMPLEMENTATION TRIAL OF A CLINICAL GUIDANCE FRAMEWORK S Aldous; on behalf of the IcareACS team CLINICAL GUIDANCE FRAMEWORKS Protracted investigation of patients presenting to emergency departments with symptoms suggesting acute coronary syndromes (ACS) is a major hospital burden. Clinical Guidance Frameworks, which assist medical decision making, can improve the accuracy of diagnosis and facilitate more timely definitive care, or discharge from hospital if significant pathology is excluded 1
2 ACCELERATED DIAGNOSTIC PROTOCOLS A component of the guidance framework, an Accelerated Diagnostic Protocol (ADP), can provide direction regarding clinical risk stratification and interpretation of early biochemical markers so that an earlier, safe discharge from hospital can be achieved. An ADP can combine variables usually including cardiac troponin (ctn) results, ECG results and objective scoring of clinical variables. ADPs allow blood sampling for ctn measurement at early time-points in patients who are low risk by the other variables. This allows clinicians to rapidly proceed to the same next step in clinical management (such as cardiac stress test, imaging and/or discharge) as would have occurred using a more prolonged time course for serial troponin testing to exclude AMI. ADP RESULTS FROM CHRISTCHURCH The ASia Pacific Evaluation of Chest pain Trial (ASPECT) was an observational study of 3582 patients presenting with to the ED with acute chest pain. Christchurch Hospital contributed 1000 patients. 421 (11 8%) patients had 30 day MACE. 9.8% were classified low risk by the ASPECT ADP Modified TIMI=0 No new ischaemic ECG changes No elevation of any 0/2h biomarkers in a POC multimarker panel. MACE occurred in 0 9% of low risk patients Sensitivity 99 3% (95% CI ) NPV 99 1% ( ) 2
3 ADP RESULTS FROM CHRISTCHURCH h Accelerated Diagnostic protocol to Assess Patients with chest pain symptoms using contemporary Troponins as the Only biomarker (ADAPT) was a sub-study of ASPECT including 1975 patients. 302 (15.3%) had a 30 day MACE. 19.8% were classified as low risk by the ADAPT ADP Modified TIMI=0 No new ischaemic ECG changes No elevation of 0/2h laboratory ctn MACE occurred in 1 (0.25%) of low risk patients Sensitivity 99.7% (98.1% to 99.9%) NPV 99.7% (98.6% to 100.0%) ADP RESULTS FROM CHRISTCHURCH Development of new risk stratification ADP (EDACS) ADAPT cohort (1974 patients, 30 day MACE rate 15.5%) 37 potential candidate variables including age, gender, symptoms, PMH/risk factors, medication, observations and using boot strapping to aim for sensitivity of 99% for 30 day MACE whilst maintaining the highest specificity possible. Sensitivity 99.0% ( ); Low risk 42.4% (ASPECT 9.8%, ADAPT 19.8%). Validated: Combined TIMI RCT and Australian cohort (608 patients, 30 day MACE rate 13.0%) Sensitivity 100% ( ); Low risk population of 51.3% Vancouver cohort (763 patients, 10% AMI) Sensitivity 100% ( ); Low risk population of 41.6% 3
4 MINISTRY OF HEALTH This successful transition at Christchurch Hospital prompted the New Zealand Ministry of Health to mandate all hospitals to implement Clinical Guidance Frameworks for possible ACS. The actual Clinical Guidance Framework or ADP to be used is not specified by the Ministry as minimal data exists of head-to-head comparisons (even observationally) between strategies. AIM To evaluate the safety and effectiveness of adopting Clinical Guidance Frameworks for possible ACS across the New Zealand National Health system by evaluating their adoption in 7 diverse hospitals. The hypothesis was that introducing the guidance frameworks would increase the proportion of patients safely discharged home within six hours of presentation to ED. 4
5 METHODS - DESIGN The study design was a pragmatic stepped-wedge implementation trial of guidance frameworks with 6 months control (or pre-implementation) and at least 4 months intervention (or post implementation). A stepped-wedge design involves sites beginning the study one after another. This means that later sites could benefit from lessons learnt from earlier sites on how to best manage the change of practice. METHODS - SETTING Sites (acute hospitals) were included if they were willing to participate and intended to implement a guidance framework incorporating an ADP by 1 September This allowed at least four months post-implementation data to be collected from all sites by the end of the study. Sites were not eligible if they had a pre-existing clinical pathway or ADP for suspected ACS. There were no restrictions regarding ctn assay/adp or clinical guidance framework. 5
6 METHODS - IMPLEMENTATION Participating sites were presented with evidence regarding published ADPs including ADAPT, EDACS, HEART, NACPR, TRAPID-AMI and the Vancouver Chest pain rule, and then chose which ADP they would use. Blood sampling for ctn was to be done on arrival and then at either 1, 2 or 3 hours after presentation Pre-implementation, there were meetings involving primary investigator MT and representatives from each stakeholder group Stakeholders then planned and facilitated implementation at each site. Clinical and management leaders were identified within the local health system. These people remained in contact throughout the process. In one hospital there was a local independent change management process. METHODS DATA COLLECTION The data collection process was pre-planned and developed before study commencement. Participants were identified from electronic diagnostic laboratory records of all patients who had blood drawn in the ED for a troponin test. Each laboratory record is linked to a patient s NHI. Using the NHI, each hopitals Decision Support department could pull basic demographic data including age, gender and ethnicity as well as follow-up data on all readmission ICD10 codes. The national mortality dataset (Ministry of Health) was used to capture deaths within the 30 day follow-up time frame. Additional data was collected on those discharged within 6 hours coded as having an adverse event by contacting the local hospital clinicians, GPs and/or patients. 6
7 METHODS - OUTCOMES The primary outcome: Proportion successfully discharged home within 6h (no major adverse cardiac event (MACE) during the following 30 days). MACE included: Death Cardiac arrest, (ICD10 codes I46.0, 46.1, 46.9) Emergency revascularization procedure Cardio-genic shock (R57.0) Ventricular arrhythmia (I47.2), ventricular fibrillation (I49.0) High-degree atrioventricular block needing intervention (I44.2) Acute myocardial infarction (I21.0, 21.1, 21.2, 21.3, 21.4, 21.9, 22.0, 22.1, 22.8, 22.9). Secondary outcomes included: Proportion of patients discharged within 6 hours who had a MACE within 30 days Lengths of stay in hospital in patients without ACS RESULTS - SITES 7
8 RESULTS SITE DEMOGRAPHICS Site ED attendance Total people in DHB Waikato 68, ,310 Hutt 44, ,378 North Shore 49, ,555 Wellington 52, ,704 Wairarapa 15,841 41,112 Waitakere 41, ,555 Middlemore 96, ,293 RESULTS PATIENT DEMOGRAPHICS Pre-Implementation Post-implementation Site Number % % Mean Number % % Mean female Maori age female Maori age Waikato Hutt North Shore Wellington Wairarapa Waitakere Middlemore
9 RESULTS CHOSEN ADP Site ctn Assay ECG criteria Risk stratification Waikato hs-ctnt at 0/2h Ischaemic (not known to be old) EDACS Hutt hs-ctnt at 0/2h Ischaemic (not known to be old) EDACS North Shore ctni at 0/2h Ischaemic TIMI Wellington hs-ctnt at 0/2h Ischaemic (not known to be old) EDACS Wairarapa hs-ctnt at 0/2h Ischaemic (not known to be old) EDACS Waitakere ctni at 0/2h Ischaemic TIMI Middlemore hs-ctni at 0/3h Dynamic ST changes EDACS RESULTS PRIMARY OUTCOME Pre-Implementation The proportion of study patients discharged within 6 hours increased in every hospital with an overall change from 8.3% to 18.4%. Post-implementation Site % MACE % Successful discharge % MACE % Successful discharge within 6h within 6h Waikato Hutt North Shore Wellington Wairarapa Waitakere Middlemore
10 RESULTS ADVERSE EVENTS In the control cohort, 5 out of 962 patients (0.52%) discharged within 6 hours had a MACE within 30 days (1 NSTEMI, 4 Deaths). In the intervention cohort, 16 out of 3632 patients (0.44%) discharged within 6 hours had a MACE within 30 days (8 NSTEMI, 1 STEMI, 1 Ventricular Tachycardia, 1 Cardiac Arrest and 5 Deaths). The sensitivity for 30-day MACE or mortality did not change with guidance framework implementation; p=0.28. RESULTS EVENTS PRE-IMPLEMENTATION Hospital Age/ Gender Days after index Coding Notes Review Waikato 87F 16 Death During bronchoscopy Hutt 75F 25 Death Lung cancer Hutt 78F 15 Death Cardiac - non ACS Hutt 69F 26 Death Non-cardiac Hutt 79M 23 NSTEMI NSTEMI 10
11 RESULTS EVENTS POST-IMPLEMENTATION Hospital Age/ Days after Coding Notes Review Gender index Wairarapa 51F 1 NSTEMI Non-cardiac* Waikato 66M 28 NSTEMI NSTEMI* Waikato 56M 3 STEMI STEMI* Waikato 91M 2 NSTEMI/VT NSTEMI/VT* Waikato 77F 27 Death Stroke* Waikato 48M 0 NSTEMI NSTEMI* Wellington 83M 9 Cardiac Arrest Asystole, PPM inserted* Wellington 81M 10 NSTEMI NSTEMI, PCI* Hutt 94F 25 Death Cause unknown* Hutt 63F 25 NSTEMI NSTEMI* Hutt 84M 1 VT Non-ventricular arrhythmia** Hutt 79M 1 Death Cause unknown* North Shore 54F 2 NSTEMI Unstable angina* North Shore 79F 2 Death AAA* North Shore 73F 1 Death STEMI* North Shore 75F 0 NSTEMI ESRF, CP, +ve ctn* RESULTS LENGTH OF STAY Non-ACS patients hospital length of stay was shorter (p<0.001), with a median reduction in hospital length of stay of 2.9h Pre-implementation Post-implementation Site Hospital LoS (days) Hospital LoS (days) p Waikato 1.2 ( ) 1.2 ( ) Hutt 0.4 ( ) 0.3 (0.2-2) <0.001 North Shore 1.2 ( ) 1.0 ( ) <0.001 Wellington 0.9 ( ) 0.7 ( ) <0.001 Wairarapa 0.8 ( ) 0.6 ( ) 0.37 Waitakere 1.1 ( ) 1.0 ( ) Middlemore 1.1 ( ) 1.1( )
12 CONCLUSION This study demonstrated that a clinical framework incorporating accelerated diagnostic pathways for patients with suspected acute coronary syndromes can be safely implemented into multiple EDs across a country over a short time interval. This indicates that national adoption of similar guidance frameworks would be possible in many countries. After implementation at each site, a greater proportion of patients were discharged within 6 hours without compromising safety. This released thousands of hours of time for medical staff and resources which could be used for other sick patients. In addition, more rapid investigative process allows patients to be reassured earlier that they are not having a heart attack and to return at an earlier time point to their families and normal life activities including work. LIMITATIONS More ideal to prospectively recruit individual patients and collect electronic data on each individual patient, but the grant for the research was insufficient to allow for this type of study. Hospitals do not automatically record which patients are being investigated for ACS, so we had to rely on serial troponin measurements to capture the population of interest We had to rely on ICD10 coding to quantify clinical outcomes. We were unable to identify admissions and deaths outside New Zealand. 12
13 ICAREACS TEAM Allan S. M. D. Jaffe ; Andrew Kerr ; Bernhard Kuepper ; Brad Peckler ; Chris Florkowski ; Chris Frampton ; David Smyth ; Denise Aitken ; Frank Peacock; Gerard Devlin ; Greg Hamilton ; Gregor Larkin ; Jaimi Greenslade ; Jeremy Dryden ; Jo Deely; John Bonning ; John Pickering ; Kate Allan ; Kim Yates ; Laura Chapman ; Louise Cullen ; Mark Simmonds ; Mark Richards ; Michael Ardagh ; Niels van Pelt ; Peter Freeman ; Peter George ; Pieter Van Wyk ; Richard Troughton ; Sally Lord ; Steve Goodacre ; Sue Crengle] ; Tim Matthews ; Tony Scott ; Vince Lambourne ; Yawane Jansz 13
Low concentrations of high-sensitivity troponin T at presentation to the
Title Page Low concentrations of high-sensitivity troponin T at presentation to the Emergency Department. Running head: Early rule-out using high-sensitivity troponin T Article Type: Letter to the Editor
More informationUnnecessary hospitalisation and investigation of low risk patients presenting to hospital with chest pain
Unnecessary hospitalisation and investigation of low risk patients presenting to hospital with chest pain Michael Perera Advanced Trainee in General and Acute Medicine Leena Aggarwal Director, Medical
More informationKeywords Acute coronary syndromes, High sensitivity cardiac markers, Malta, Troponin T, Myocardial infarction
Did the introduction of high-sensitivity Troponin T for the assessment of suspected acute coronary syndrome in Malta result in reduction of hospitalization time? A retrospective review Ahmed Chilmeran,
More information2-Hour Accelerated Diagnostic Protocol to Assess Patients With Chest Pain Symptoms Using Contemporary Troponins as the Only Biomarker
Journal of the American College of Cardiology Vol. 59, No. 23, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.035
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Early rule out or diagnosis of acute myocardial infarction: High-sensitivity troponin tests (Elecsys troponin T high-sensitive, ARCHITECT STAT highsensitivity
More information10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationValidation of an accelerated high-sensitivity troponin T assay protocol in an Australian cohort with chest pain
Elevation of cardiac troponin (ctn) levels is central to the definition of acute myocardial infarction (AMI). 1 Increasingly sensitive ctn assays offer the potential for AMI to be diagnosed earlier than
More informationD DAVID PUBLISHING. 1. Introduction. 2. Methods. Samira Green 1, Vanessa Jessop 2, Jason Pott 2 and Tim Harris 2
Journal of Health Science 2 (2014) 523-528 doi: 10.17265/2328-7136/2014.11.001 D DAVID PUBLISHING Management, Triage and Outcomes of 378 Patients Presenting to the Emergency Department with Chest Pain
More informationHigh Sensitivity Troponin Improves Management. But Not Yet
High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationHit the road Jack! W. FRANK PEACOCK, MD, FACEP, FACC
Hit the road Jack! W. FRANK PEACOCK, MD, FACEP, FACC Visits 130,000,000 annually 10.4 M chest pain (8.0%) 4.1 M sent home non-cardiac 6.24 M suspected or actual cardiac 50,000 MIs 3.1 M non-cardiac (50%)
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationThe utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department
Accepted Manuscript The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department John W. Pickering, Joanna M. Young, Peter George,
More informationRecent community campaigns on
Availability of highly sensitive troponin assays and acute coronary syndrome care: insights from the SNAPSHOT registry Use of hs troponin testing of patients hospitalised with possible ACS was associated
More informationDolore Toracico e Livelli di Troponina non Misurabili
Dolore Toracico e Livelli di Troponina non Misurabili Andrea Fabbri Dipartimento di Emergenza Presidio Ospedaliero Morgagni Pierantoni Azienda USL Romagna Forlì andrea.fabbri@auslromagna.it Rapid Exclusion
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationCurrent Utilities of Cardiac Biomarker Testing at POC. June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN
Current Utilities of Cardiac Biomarker Testing at POC June 24, 2010 Joe Pezzuto, MT (ASCP) Carolyn Kite, RN 1. Discuss challenges associated with diagnosing Acute Coronary Syndromes (ACS) and Heart Failure
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Date: Location: Speaker: ACC 2015 PREVIEW Monday, March 9, 2015, 7:00 8:00 AM ANW Education Building, Watson Room Elevated Troponin in Patients Presenting to the Emergency
More informationACLS/ACS Updates 2015
ACLS/ACS Updates 2015 Advanced Cardiovascular Life Support by: Fareed Al Nozha, JBIM, ABIM, FKFSH&RC(Cardiology) Consultant Cardiologist Faculty, National CPR Committee, ACLS Program Head, SHA Dr Abdulhalim
More informationHigh-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor
More informationImpact of use of the HEART score in chest pain patients. Judith Poldervaart, MD, PhD Julius Center
Impact of use of the HEART score in chest pain patients Judith Poldervaart, MD, PhD Julius Center The HEART-score Diagnostic risk score for chest pain patients at ED 5 clinical elements Supports direct
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationCoronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study
Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationBioRemarkable Symposium
BACC BioRemarkable Symposium Acute Myocardial infarction Stefan Blankenberg University Heart Center Hamburg London, September 7th, 2017 Universitätsklinikum Hamburg-Eppendorf Third Universal-Definition
More informationEARLY DIAGNOSIS AND RISK STRATIFICATION IN PATIENTS WITH SYMPTOMS SUGGESTIVE OF ACUTE CORONARY SYNDROME
DEPARTMENT OF CLINICAL SCIENCE AND EDUCATION, SÖDERSJUKHUSET Karolinska Institutet, Stockholm, Sweden EARLY DIAGNOSIS AND RISK STRATIFICATION IN PATIENTS WITH SYMPTOMS SUGGESTIVE OF ACUTE CORONARY SYNDROME
More informationDiagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, e, ARCHITECT STAT T High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics guidance
More informationDiagnostics consultation document
National Institute for Health and Care Excellence Diagnostics consultation document Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive,
More informationTHE EVIDENCED BASED 2015 CPR GUIDELINES
SAUDI HEART ASSOCIATION NATIONAL CPR COMMITTEE THE EVIDENCED BASED 2015 CPR GUIDELINES Page 1 Chapter 7 ACS CHAPTER DIAGNOSTIC INTERVENTIONS IN ACS Prehospital ECG ILCOR Treatment Recommendation: We recommend
More informationBMJ Open. For peer review only -
BMJ Open Change to costs and lengths of stay in the emergency department and the Brisbane Accelerated CHest pain (BACH) protocol: an observational study Journal: BMJ Open Manuscript ID: bmjopen-0-00 Article
More informationUndetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung, MD, PhD; Magnus Johansson, MD, PhD; Martin Holzmann,
More informationRESPONSES TO COMMENTS ON: Recommendations for Use of Point-of-Care (POC) Troponin Assays in Assessment of Acute Coronary Syndrome
RESPONSES TO COMMENTS ON: Recommendations for Use of Point-of-Care (POC) Troponin Assays in Assessment of Acute Coronary Syndrome Page 1 Responses were received from: 1. Chemical Pathology Clinical Stream,
More informationRapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com
More informationVCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE
VCU HEALTH SYSTEM EMERGENCY DEPARTMENT GUIDELINE SUBJECT: Care of the Chest Pain Patient in the Emergency Department FILE SECTION: VCUHS/ED Section: Please note: Clinical Practice Guideline Evidence-based
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationIs it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention
Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention DA Jones, J Howard, S Gallagher, KS Rathod, A Jain, S Mohiddin, C Knight, A Mathur, EJ
More informationDr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)
Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton Dr Joan Leighton General Practitioner Heart Foundation Christchurch 14:00-14:55 WS #106: Whats
More informationThe clinical performance of the novel POC Minicare ctni-assay. Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden
The clinical performance of the novel POC Minicare ctni-assay Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden Disclosure: Per Venge has received consultancy honoraria
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationMario Cavazza Medicina d Urgenza e Pronto Soccorso Azienda Ospedaliero Universitaria di Bologna
Mario Cavazza Medicina d Urgenza e Pronto Soccorso Azienda Ospedaliero Universitaria di Bologna In the emergency physicians perspective, the rapid identification of high risk patients and the concomitant
More informationDevelopment and validation of the Emergency Department Assessment of Chest pain Score and 2 h accelerated diagnostic protocol
bs_bs_banner Emergency Medicine Australasia (2014) 26, 34 44 doi: 10.1111/1742-6723.12164 RESEARCH Development and validation of the Emergency Department Assessment of Chest pain Score and 2 h accelerated
More informationIschaemic cardiovascular disease
Ischaemic cardiovascular disease What are the PHO performance programme indicators and how are they best achieved? 40 BPJ Issue 36 Supporting the PHO Performance Programme The PHO Performance Programme
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationJournal of the American College of Cardiology Vol. 62, No. 14, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 62, No. 14, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.078
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationProspective Validation of a Clinical Decision Rule to Identify ED Chest Pain Patients Who Can Safely be Removed from Cardiac Monitoring
Prospective Validation of a Clinical Decision Rule to Identify ED Chest Pain Patients Who Can Safely be Removed from Cardiac Monitoring Department of Emergency Medicine CAEP 2015 Shahbaz Syed PGY 3 FRCP
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationNHS QIS National Measurement of Audit Acute Coronary Syndrome
NHS QIS National Measurement of Audit Acute Coronary Syndrome Things have changed based on the experience and feedback from the first cycle of measurement and, for the better we think! The Acute Coronary
More information7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay
Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member
More informationJAWDA Quarterly Waiting Time Guidelines for (Specialized and General Hospitals)
JAWDA Waiting Time Guidelines for (Specialized and General Hospitals) January 2019 Page 1 of 22 Table of Contents Executive Summary... 3 About this Guidance... 4 Performance Indicators... 5 APPENDIX -
More information1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11
May 2011 1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11 Yes b) If confirmed please provide details on the number of
More information2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction
2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction Ramzi Khalil MD FACC Assistant Professor Allegheny Gen.Hospital AHN Speakers
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationImpact of in-hospital delay to invasive treatment of NSTEMI patients on early and 12-month clinical outcomes
Impact of in-hospital delay to invasive treatment of NSTEMI patients on early and 12-month clinical outcomes Analysis from the PL-ACS Registry Marek Gierlotka 1, Grzegorz Opolski 2, Lech Poloński 1, Marcin
More informationImpact of Troponin Performance on Patient Care
Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable
More informationKing County EMS STEMI Patients Receiving PCI at King County Hospitals in 2012
King County EMS STEMI Patients Receiving PCI at King County Hospitals in 2012 Objective The goal of this report is to evaluate demographics, pre hospital and hospital response times and outcomes of ST
More informationBenoy N Shah 1,2,3, Gothandaraman Balaji 1, Abdalla Alhajiri 1, Ihab Ramzy 1, Shahram Ahmadvazir 1 & Roxy Senior 1,2,3
STRESS ECHOCARDIOGRAPHY PREDICTS ALL-CAUSE MORTALITY IN PATIENTS ADMITTED WITH SUSPECTED ACUTE CORONARY SYNDROME, NON-DIAGNOSTIC ECG AND NEGATIVE TROPONIN European Society of Cardiology Annual Congress
More informationHigh-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective Evaluation
Clinical Chemistry 61:7 983 989 (2015) Proteomics and Protein Markers High-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective
More informationPart 9: Acute Coronary Syndromes 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Part 9: Acute Coronary Syndromes 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Robert E. O Connor, Chair; Abdulaziz S. Al Ali; William
More informationWhat is the Yield of Testing for Coronary Artery Disease after an Emergency Department Attendance with Chest Pain?
Heart, Lung and Circulation (2016) 25, 12 18 1443-9506/04/$36.00 http://dx.doi.org/10.1016/j.hlc.2015.05.025 ORIGINAL ARTICLE What is the Yield of Testing for Coronary Artery Disease after an Emergency
More informationCommon Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationPatients presenting with chest
Cost and outcomes of assessing patients with chest pain in an Australian emergency department The current guidelinebased process of assessment is lengthy, costly and consumes significant resources Louise
More informationHigh Value Evaluation of Chest Pain. Zoom Tips
High Value Evaluation of Chest Pain California Quality Collaborative s Cardiology Webinar Series Webinar 1 December 7, 2017 Zoom Tips Attendees are automatically MUTED upon entry Refrain from using the
More informationPreliminary Programme
Preliminary Programme The scientific programme comprises various styles of presentations and sessions, each offering a unique opportunity to amass new and important scientific information. Optimal management
More informationEarly Rule-Out and Rule-In Strategies for Myocardial Infarction
Papers in Press. Published October 10, 2016 as doi:10.1373/clinchem.2016.254730 The latest version is at http://hwmaint.clinchem.aaccjnls.org/cgi/doi/10.1373/clinchem.2016.254730 Clinical Chemistry 63:1
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationPreoperative tests (update)
National Institute for Health and Care Excellence. Preoperative tests (update) Routine preoperative tests for elective surgery NICE guideline NG45 Appendix C: April 2016 Developed by the National Guideline
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationIFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid 1 CREATED By the EB in 2011, following to the Committee on Standardization of Cardiac
More informationRapid Disposition of Chest Pain Patients February 2019
UCSF High Risk Emergency Medicine Rapid Disposition of Chest Pain Patients February 2019 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International
More informationREGIONAL DIFFERENCES IN HF SERVICE DEMAND AND DELIVERY
REGIONAL DIFFERENCES IN HF SERVICE DEMAND AND DELIVERY Raewyn Fisher, Waikato Hospital On behalf of Midland Cardiac Network (With thanks to Population Health data analysts) Cardiac Network Plans (Midland)
More informationEmergency Medicine Updates. Dr. Timothy Cobb March 1, 2018
Emergency Medicine Updates Dr. Timothy Cobb March 1, 2018 Topics Chest pain Renal colic Atrial fibrillation Pediatric head trauma Asymptomatic hypertension Chest Pain Non traumatic chest pain 2nd most
More informationDoes serial troponin measurement help identify acute ischemia/ischemic events?
Does serial troponin measurement help identify acute ischemia/ischemic events? Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine and Laboratory Medicine & Pathology
More informationUniversity of Bristol - Explore Bristol Research
Rogers, C., Capoun, R., Scott, L., Taylor, J., Angelini, G., Narayan, P.,... Ascione, R. (2017). Shortening cardioplegic arrest time in patients undergoing combined coronary and valve surgery: results
More informationPredictive significance of detectable cardiac troponin I measured with a contemporary-sensitive assay in a real life experience
Original Article Page 1 of 5 Predictive significance of detectable cardiac troponin I measured with a contemporary-sensitive assay in a real life experience Laura Bonfanti 1, Giuseppe Lippi 2, Irene Ciullo
More informationAssociate Professor Gerry Devlin
Associate Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton 9:00-9:15 Secondary Prevention of IHD The Challenge of Secondary Prevention Associate
More informationCongreso Nacional del Laboratorio Clínico 2016
Can biomarkers help us make a better use of cardiac imaging for myocardial ischaemia rule-out in the Emergency Department? Alessandro Sionis Director Acute and Intensive Cardiac Care Unit Hospital de la
More informationOUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION
OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION FEROZ MEMON*, LIAQUAT CHEEMA**, NAND LAL RATHI***, RAJ KUMAR***, NAZIR AHMED MEMON**** OBJECTIVE: To compare morbidity,
More informationTransfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem
Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927
More informationOP Chest Pain General Data Element List. All Records All Records. All Records All Records All Records. All Records. All Records.
Material inside brackets ([and]) is new to this Specifications Manual version. Hospital Outpatient Quality Measures Chest Pain (CP) Set Measure ID # OP-4 * OP-5 * Measure Short Name Aspirin at Arrival
More informationAcute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita
More informationGUIDELINE 14 ACUTE CORONARY SYNDROMES
AUSTRALIAN RESUSCITATION COUNCIL GUIDELINE 14 ACUTE CORONARY SYNDROMES OVERVIEW AND SUMMARY As a part of the International Liaison Committee on Resuscitation (ILCOR) process that led to the International
More informationOver-diagnosis in pathology testing and the impact on patients
Over-diagnosis in pathology testing and the impact on patients Sally Lord MBBS, MS(Epi) School of Medicine, The University of Notre Dame NHMRC Clinical Trials Centre, The University of Sydney Landmark
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationSupplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.
Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationZoll Medical--LifeVest:
Zoll Medical--LifeVest: Territory Manager: Sunny Brown Cell: (818) 916-6520 Objectives Why the LifeVest device exist Review indications for Wearable Cardioverter Defibrillator (WCD) use Give a brief description
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationCoronary Angiography after Cardiac Arrest without ST-Segment Elevation: the COACT trial
Coronary Angiography after Cardiac Arrest without ST-Segment Elevation: the On behalf of the COACT investigators Jorrit Lemkes, MD, Interventional cardiologist Amsterdam UMC, Vrije Universiteit Amsterdam,
More information